These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 20425517)

  • 21. Bone disease in the setting of HIV infection: update and review of the literature.
    Castronuovo D; Cacopardo B; Pinzone MR; Di Rosa M; Martellotta F; Schioppa O; Moreno S; Nunnari G
    Eur Rev Med Pharmacol Sci; 2013 Sep; 17(18):2413-9. PubMed ID: 24089217
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HIV infection and osteoporosis: pathophysiology, diagnosis, and treatment options.
    Rothman MS; Bessesen MT
    Curr Osteoporos Rep; 2012 Dec; 10(4):270-7. PubMed ID: 23100110
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Diagnosis, prevention, and treatment of bone fragility in people living with HIV: a position statement from the Swiss Association against Osteoporosis.
    Biver E; Calmy A; Aubry-Rozier B; Birkhäuser M; Bischoff-Ferrari HA; Ferrari S; Frey D; Kressig RW; Lamy O; Lippuner K; Suhm N; Meier C
    Osteoporos Int; 2019 May; 30(5):1125-1135. PubMed ID: 30603840
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reduced bone mineral density in human immunodeficiency virus-infected individuals: a meta-analysis of its prevalence and risk factors.
    Goh SSL; Lai PSM; Tan ATB; Ponnampalavanar S
    Osteoporos Int; 2018 Mar; 29(3):595-613. PubMed ID: 29159533
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Protecting bone in long-term HIV positive patients receiving antiretrovirals.
    McGinty T; Mallon P
    Expert Rev Anti Infect Ther; 2016 Jun; 14(6):587-99. PubMed ID: 27189695
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adverse effects of antiretroviral therapy: focus on bone density.
    Viganò A; Mora S
    Expert Opin Drug Saf; 2004 May; 3(3):199-208. PubMed ID: 15155148
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Osteoporosis and bone health in HIV.
    Powderly WG
    Curr HIV/AIDS Rep; 2012 Sep; 9(3):218-22. PubMed ID: 22581359
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prevalence of and risk factors for low bone mineral density in Spanish treated HIV-infected patients.
    Cervero M; Torres R; Agud JL; Alcázar V; Jusdado JJ; García-Lacalle C; Moreno S
    PLoS One; 2018; 13(4):e0196201. PubMed ID: 29709013
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-Term Stable Bone Mineral Density in HIV-Infected Men Without Risk Factors for Osteoporosis Treated with Antiretroviral Therapy.
    Bolland MJ; Horne AM; Briggs SE; Thomas MG; Reid IR; Gamble GD; Grey A
    Calcif Tissue Int; 2019 Oct; 105(4):423-429. PubMed ID: 31250043
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Decreased bone mineral density in HIV-infected children receiving highly active antiretroviral therapy].
    Rojo Conejo P; Ramos Amador JT; García Piñar L; Ruano Fajardo C; Sánchez Granados JM; González Tomé MI; Ruiz Contreras J
    An Pediatr (Barc); 2004 Mar; 60(3):249-53. PubMed ID: 14987516
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bone mass loss and vitamin D metabolism impairment in HIV patients receiving highly active antiretroviral therapy.
    Madeddu G; Spanu A; Solinas P; Calia GM; Lovigu C; Chessa F; Mannazzu M; Falchi A; Mura MS; Madeddu G
    Q J Nucl Med Mol Imaging; 2004 Mar; 48(1):39-48. PubMed ID: 15195003
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Decreased bone mineral density and increased fracture risk in aging men with or at risk for HIV infection.
    Arnsten JH; Freeman R; Howard AA; Floris-Moore M; Lo Y; Klein RS
    AIDS; 2007 Mar; 21(5):617-23. PubMed ID: 17314524
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review.
    Brown TT; Qaqish RB
    AIDS; 2006 Nov; 20(17):2165-74. PubMed ID: 17086056
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Continuous antiretroviral therapy decreases bone mineral density.
    Grund B; Peng G; Gibert CL; Hoy JF; Isaksson RL; Shlay JC; Martinez E; Reiss P; Visnegarwala F; Carr AD;
    AIDS; 2009 Jul; 23(12):1519-29. PubMed ID: 19531929
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Spontaneous supracondylar femoral fracture in an HIV patient in lotus position.
    Pinto Neto LF; Eis SR; Miranda AE
    J Clin Densitom; 2011; 14(1):74-6. PubMed ID: 21295744
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of alendronate on HIV-associated osteoporosis: a randomized, double-blind, placebo-controlled, 96-week trial (ANRS 120).
    Rozenberg S; Lanoy E; Bentata M; Viard JP; Valantin MA; Missy P; Darasteanu I; Roux C; Kolta S; Costagliola D;
    AIDS Res Hum Retroviruses; 2012 Sep; 28(9):972-80. PubMed ID: 22353022
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Bone mineral density and fracture risk in patients with ankylosing spondylitis].
    Madsen OR
    Ugeskr Laeger; 2008 Nov; 170(48):3956-60. PubMed ID: 19087736
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bone alterations associated with HIV.
    Warriner AH; Mugavero M; Overton ET
    Curr HIV/AIDS Rep; 2014 Sep; 11(3):233-40. PubMed ID: 25064454
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 4th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. San Diego, California, USA 22-25 September 2002.
    Nolan D; Christiansen F
    Expert Opin Drug Saf; 2003 Jan; 2(1):95-101. PubMed ID: 12904128
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bone loss in the HIV-infected patient: evidence, clinical implications, and treatment strategies.
    Walker Harris V; Brown TT
    J Infect Dis; 2012 Jun; 205 Suppl 3(Suppl 3):S391-8. PubMed ID: 22577213
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.